Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Authorization Safety Study (PASS) to Further Evaluate Real-World Safety in Patients With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma

NCT07353099 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT07353099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07353099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Authorization Safety Study (PASS) to Further Evaluate Real-World Safety in Patients With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma
Lead sponsor
Takeda
Phase
Observational
Overall status
Recruiting
Start date
May 26, 2026
Completion date
April 1, 2030
Enrollment
50 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

thrombotic thrombocytopenic purpura (ttp)